Product information and disease descriptionProduct description
Phase of product development
9 evidence topics · 11 sources
Investigational status and development phase
Regulatory status: Submission planned; NDA submission anticipated in 2028
Launch
No evidence found.
Anticipated milestones: phase 3 topline data and study completion dates
Development history: phase 1/2 study start and status
Development history: phase 3 and extension study start
FDA orphan drug designation
FDA Fast Track designation
FDA feedback on the phase 3 design
Regulatory designations outside the United States
No evidence found.